What makes Stelara (ustekinumab) so expensive?
Stelara is expensive mainly because it is a branded biologic: it’s made from living cells using complex manufacturing and quality controls, and it can’t be easily replicated like standard small-molecule drugs. Ustekinumab also typically has limited competition in many markets, so the branded manufacturer maintains pricing power for longer than with older generic drugs.
Does patent protection or exclusivity play a role?
Yes. When a drug is still under patent and market exclusivity, there are fewer (or no) lower-cost biosimilar alternatives available, which keeps prices high. Over time, biologic competition can reduce costs, but it depends on whether biosimilars are approved and actually priced aggressively in a given country and payer system.
How does it compare with other biologics and biosimilars?
Biologics often carry high list prices across the class (for example, TNF inhibitors and other immune-modulating therapies). Even within the same class, the presence or absence of biosimilar competition can create large price differences. When biosimilars enter, costs usually move down, though not always to the level people expect, because of contracting terms, rebates, and formulary positioning.
Why are the costs also driven by dosing and long-term use?
Stelara is used chronically for conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease or ulcerative colitis, depending on the patient and regimen. Even when the drug’s per-dose cost is known, the total annual spend can be very high because patients may stay on treatment for years.
What’s the role of insurance coverage, rebates, and list vs. net price?
What patients see as “the price” is often a mix of list price and negotiated payer pricing. Insurers usually negotiate discounts or rebates, but patients’ out-of-pocket costs can still be high due to deductibles, coinsurance rules, prior authorization requirements, and how pharmacy benefits manage specialty drugs.
Are there cheaper alternatives?
In many systems, lower-cost options can include:
- Biosimilars (if and where they are available for ustekinumab or interchangeable products)
- Switching to a different biologic with better coverage
- Using alternative dosing strategies permitted by the prescribing label and payer rules
Whether these reduce cost depends on a patient’s insurance plan and formulary.
Where to check pricing and competitive landscape
For a drug-level look at patents and the broader competitive context, DrugPatentWatch.com is a useful resource: https://www.drugpatentwatch.com/